Literature DB >> 11886256

Equine herpesvirus type 1 devoid of gM and gp2 is severely impaired in virus egress but not direct cell-to-cell spread.

Jens Rudolph1, Nikolaus Osterrieder.   

Abstract

Experiments were conducted to analyze the effects of a simultaneous deletion of glycoprotein M (gM) and glycoprotein 2 (gp2) of equine herpesvirus type 1 (EHV-1). EHV-1 strain RacH was cloned as a bacterial artificial chromosome (pRacH) by homologous recombination of a mini F plasmid into the unique short region of the genome, thereby deleting gene 71 encoding gp2. Upon transfection of the pRacH DNA into rabbit kidney RK13 cells, virus plaques were visible from day 1 after transfection. The mutant RacH virus (H Delta gp2) reconstituted from pRacH lacked gene 71 and did not express gp2 as assayed by indirect immunofluorescence analysis using gp2-specific monoclonal antibodies. The H Delta gp2 virus exhibited 10-fold reduced extracellular titers and an approximately 10% reduction in mean plaque diameters when compared to parental or gp2-revertant virus. The gM open reading frame was deleted from pRacH by recE/T mediated mutagenesis in Escherichia coli. The gM-gp2 double negative virus mutant (H Delta gp2gM) did not express either of the deleted glycoproteins as demonstrated by indirect immunofluorescence analysis. The H Delta gp2gM virus exhibited a 200-fold reduction of end-point extracellular titers when compared to parental RacH virus, which could not be compensated for by growth of the mutant virus on gM-expressing cells. After restoration of the gM open reading frame, however, growth of the mutant virus was comparable to the H Delta gp2 virus. Plaque diameters of the gM-gp2 double-negative mutant were reduced by only 16% when compared to that of parental RacH virus. From the results it was concluded that the simultaneous absence of gM and gp2 had an additive effect on egress but not secondary envelopment or cell-to-cell spread of EHV-1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11886256     DOI: 10.1006/viro.2001.1277

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Identification and characterization of equine herpesvirus type 1 pUL56 and its role in virus-induced downregulation of major histocompatibility complex class I.

Authors:  Guanggang Ma; Silke Feineis; Nikolaus Osterrieder; Gerlinde R Van de Walle
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

2.  In vitro and in vivo relevance of infectious laryngotracheitis virus gJ proteins that are expressed from spliced and nonspliced mRNAs.

Authors:  Walter Fuchs; Dorothee Wiesner; Jutta Veits; Jens P Teifke; Thomas C Mettenleiter
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Potential of equine herpesvirus 1 as a vector for immunization.

Authors:  Sascha Trapp; Jens von Einem; Helga Hofmann; Josef Köstler; Jens Wild; Ralf Wagner; Martin Beer; Nikolaus Osterrieder
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Equine herpesvirus 1 entry via endocytosis is facilitated by alphaV integrins and an RSD motif in glycoprotein D.

Authors:  Gerlinde R Van de Walle; Sarah T Peters; Brian C VanderVen; Dennis J O'Callaghan; Nikolaus Osterrieder
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

5.  Varicella-zoster virus glycoprotein M homolog is glycosylated, is expressed on the viral envelope, and functions in virus cell-to-cell spread.

Authors:  Yoshiaki Yamagishi; Tomohiko Sadaoka; Hironori Yoshii; Pranee Somboonthum; Takayoshi Imazawa; Kazuhiro Nagaike; Keiichi Ozono; Koichi Yamanishi; Yasuko Mori
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

6.  A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9.

Authors:  B Karsten Tischer; Benedikt B Kaufer; Marvin Sommer; Felix Wussow; Ann M Arvin; Nikolaus Osterrieder
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

7.  Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza.

Authors:  Cristina Rosas; Gerlinde R Van de Walle; Stephan M Metzger; Karin Hoelzer; Edward J Dubovi; Sung G Kim; Colin R Parrish; Nikolaus Osterrieder
Journal:  Vaccine       Date:  2008-03-31       Impact factor: 3.641

8.  The truncated form of glycoprotein gp2 of equine herpesvirus 1 (EHV-1) vaccine strain KyA is not functionally equivalent to full-length gp2 encoded by EHV-1 wild-type strain RacL11.

Authors:  Jens von Einem; Janet Wellington; J Millar Whalley; Kerstin Osterrieder; Dennis J O'Callaghan; Nikolaus Osterrieder
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Identification of candidate gammaherpesvirus 68 genes required for virus replication by signature-tagged transposon mutagenesis.

Authors:  Nathaniel J Moorman; Chie Yu Lin; Samuel H Speck
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  The alpha-TIF (VP16) homologue (ETIF) of equine herpesvirus 1 is essential for secondary envelopment and virus egress.

Authors:  Jens von Einem; Daniel Schumacher; Dennis J O'Callaghan; Nikolaus Osterrieder
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.